Cue Biopharma, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cue Biopharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $815.00K.
- Cue Biopharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-12-31 was $0.00.
- Cue Biopharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was $0.00.
- Cue Biopharma, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $85.00K.
- Cue Biopharma, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $473.00K.
- Cue Biopharma, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $2.60M, a 17.96% increase from fiscal 2020.
- Cue Biopharma, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $2.20M, a 17.07% increase from fiscal 2019.
- Cue Biopharma, Inc. stock issued during period, value, stock options exercised for fiscal 2019 was $1.88M, a 14954.98% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $815.00K 10-Q · filed 2026-08-14 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $473.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | |
| 2023-06-30 | $85.00K 10-Q · filed 2024-08-14 | |
| 2023-03-31 | $388.00K 10-Q · filed 2024-05-09 | |
| 2021-12-31 | $536.78K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $2.60M 10-K · filed 2023-03-21 |
| 2021-09-30 | $834.00K 10-Q · filed 2022-11-14 | $2.47M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $310.00K 10-Q · filed 2022-08-04 | $2.35M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $919.00K 10-Q · filed 2022-05-10 | $3.09M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $404.06K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $2.20M 10-K · filed 2022-03-16 |
| 2020-09-30 | $719.00K 10-Q · filed 2021-11-09 | $3.04M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $1.04M 10-Q · filed 2021-08-09 | $2.67M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $36.00K 10-Q · filed 2021-05-10 | $1.66M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $1.88M 10-K · filed 2021-03-09 |
| 2019-09-30 | $355.00K 10-Q · filed 2019-11-07 | $643.50K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $32.00K 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $257.00K 10-Q · filed 2020-05-07 | |
| 2018-12-31 | -$500.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $12.50K 10-K · filed 2020-03-12 |
| 2017-12-31 | $8.01K 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |